Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $167 | $487 | $857 | $1,879 |
| - Cash | $106 | $146 | $124 | $294 |
| + Debt | $59 | $63 | $68 | $68 |
| Enterprise Value | $121 | $404 | $802 | $1,653 |
| Revenue | $0 | $0 | $85 | $11 |
| % Growth | -53.1% | -99.8% | 695.1% | – |
| Gross Profit | $0 | $0 | $85 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$201 | -$227 | -$169 | -$201 |
| % Margin | -328,923% | -174,429.2% | -199.6% | -1,888.8% |
| Net Income | -$343 | -$235 | -$183 | -$250 |
| % Margin | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% |
| EPS Diluted | -1.31 | -0.935 | -0.741 | -1.031 |
| % Growth | -40.1% | -26.1% | 28.1% | – |
| Operating Cash Flow | -$162 | -$164 | -$170 | -$126 |
| Capital Expenditures | -$0 | -$3 | -$24 | -$66 |
| Free Cash Flow | -$163 | -$166 | -$194 | -$192 |